



probelte **pharma**

Bibliografía

- 1.** Norn, S., Clementsen, P. y Kristensen, K.S. Mediator release and its reinforcement: new aspects of microorganisms in asthma. *Pneumologia i Alergologia Polska*, 60 (2): 5-11, 1992.
- 2.** Clementsen, P., Kristensen, K.S. y Norn, S. Microorganisms and exacerbation of chronic obstructive pulmonary diseases: pathophysiological mechanisms. *Allergy*, 47: 195-202, 1992.
- 3.** Koch, C., Andersen, P., Hertz, J.B., Hoiby, N., Kappelgaard, E., Moller, N.E., Norn, S., Pedersen, M., Petersen, P.S., Skov, P.S. y Tonnesen, P. Studies on hypersensitivity to bacterial antigens in intrinsic asthma. *Allergy*, 37: 191-201, 1982.
- 4.** Oehling, A. *Alergología e Inmunología Clínica*. Ed.: McGraw-Hill-Interamericana de España, 1995.
- 5.** Brühl, P., Heinrich, J. y Hacker, J. Immuntherapie bei Harnwegsinfektionen. *Urologe (A)*, 31: 37-42, 1992.
- 6.** Nayir, A., Emre, S., Sirin, A., Bulut, A., Alpay, H. y Tanman, F. The effects of vaccination with inactivated uropathogenic bacteria in recurrent urinary tract infections of children. *Vaccine*, 13 (11): 987-990, 1995.
- 7.** Kucharska, E. Attempt to evaluation of the influence of autovaccin on patients with intrinsic asthma and chronic obstructive lung disease. *International Review of Allergology and Clinical Immunology*, 3 (1): 47-49, 1997.
- 8.** Palma-Carlos, A.G. Basic aspects of therapy in intrinsic asthma. Schmitz-Schumann, M. et al. (Ed). *Agents and Actions Supplements. Intrinsic Asthma*; 4th International Symposium, Hochgebirgsklinik Davos, Switzerland. 28 (September): 263-277, 1988.
- 9.** Grischke, E.M. y Rüttgers, H. Treatment of bacterial infections of the female urinary tract by immunization of the patients. *Urol. Int.*, 42: 338-341, 1987.
- 10.** Uehling, D.T., Hopkins, W.J., Dahmer, L.A. y Balish, E. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. *The Journal of Urology*, 152: 2308-2311, 1994.

- 11.** Uehling, D.T., Hopkins, W.J., Balish, E., Xing, Y. y Heisey, D.M. Vaginal mucosal immunization for recurrent urinary tract infection: Phase II clinical trial. *The Journal of Urology*, 157: 2049-2052, 1997
- 12.** Knaster, J. Eficacia y efectos adversos de una suspensión bacteriana administrada por vía sublingual. Estudio de Eficacia y Efectos Adversos de Autovacunas y Suspensiones Bacterianas Probelte Pharma I, Marzo, 1998.
- 13.** Roncalés, A. y Valdivia, P. Valoración inicial de la eficacia y efectos secundarios de la terapia inmune con cepas inactivadas de patógenos urinarios en pacientes con infecciones urinarias de repetición. Estudio de Eficacia y Efectos Adversos de Autovacunas y Suspensiones Bacterianas Probelte Pharma II, Julio, 1998.
- 14.** Moreno, V. La vacunación bacteriana en las patologías infecciosas y/o inflamatorias ORL. Estudio de Eficacia y Efectos Adversos de Autovacunas y Suspensiones Bacterianas Probelte Pharma III, Septiembre, 1998.
- 15.** Schulman, C.C., Corbusier, A., Michiels, H. y Taenzer, H.J. Oral immunotherapy of recurrent urinary tract infections: A double-blind placebo-controlled multicenter study. *The Journal of Urology*, 150: 917-921, 1993.
- 16.** Oehling, A., Aguila de la Coba, R., Fernández, M., Leyva, J., Sanz, M.L. y Resano, A. Potentiation of histamine release against inhalant allergens (*Dermatophagoides pteronyssinus*) with bacterial antigens in bronchial asthma. *Invest. Allergol. Clin. Immunol.*, 7(4): 211-216, July-August, 1997.
- 17.** Oehling, A.K. Bacterial infection as an important triggering factor in bronchial asthma. *Invest. Allergol. Clin. Immunol.*, 9(1): 6-13, January-February, 1999.
- 18.** Rutishauser, M., Pitzke, P., Grevers, G., Aubel, A., Elsasser, U. y Kämmerleit, A. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study. *Advances in Therapy*, 15(6): 330-341, November/December, 1998.
- 19.** Grevers, G., Palacios, O.A., Rodríguez, B., Abel, S. y Aubel, A. Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: Results of an open, prospective, multinational study. *Advances in Therapy*, 17(2): 103-116, March/April, 2000.

20. Ruah, S.B., Ruah, C., Aubel, A., Abel, S., y Elsasser, U. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. *Advances in Therapy*, 18(4): 151-162, July/August, 2001.

21. Oehling, A. Bacterial immunotherapy in bronchial asthma. *Invest. Allergol. Clin. Immunol.*, 7(1): 14-19, January-February, 1997.





Probelte Pharma, S.L.U

C/ Antonio Belmonte Abellán, 7 30100 (Murcia)

Tlf: 968 85 85 77

info@probeltepharma.es

www.probeltepharma.es